Verrica Pharmaceuticals Inc (OQ:VRCA)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 10 N High St Ste 200
WEST CHESTER PA 19380-3014
Tel: N/A
IR: See website
Key People
Paul B. Manning
Chairman of the Board
Ted W. White
President, Chief Executive Officer, Director
Chris Degnan
Chief Financial Officer
Joe Bonaccorso
Chief Commercial Officer
Patrick Burnett
Chief Medical Officer
Business Overview
Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.
Financial Overview
For the three months ended 31 March 2019, Verrica Pharmaceuticals Inc revenues was not reported. Net loss increased from $1.9M to $7.5M. Higher net loss reflects Research and development - Balancing val increase from $812K to $4.3M (expense), General and administrative - Balancing v increase from $941K to $2.9M (expense), Stock-Based Compensation in SG&A increase from $45K to $640K (expense).
Employees: 16 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $199.51M as of Mar 31, 2019
Annual revenue (TTM): $0.00M as of Mar 31, 2019
EBITDA (TTM): -$27.96M as of Mar 31, 2019
Net annual income (TTM): -$26.25M as of Mar 31, 2019
Free cash flow (TTM): -$22.90M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 25,708,485 as of May 3, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization